
09/11/2025
There are few contraindications for the use of the JAK inhibitors tofacitinib and upadacitinib for inflammatory bowel disease (IBD), and most adverse effects are mild to moderate and manageable. However, some more serious adverse effects have been associated with these medications, so risk assessment and monitoring are essential. Learn more about safety and efficacy of JAK inhibitors for IBD by enrolling in the complimentary, CCCEP-accredited, online course entitled Practical Pharmacist Strategies for Managing IBD with JAK Inhibitors.
Enrol now: https://ow.ly/y8em50WyIlu